darbepoetin alfa
information and resources from the National Cancer Institute
NCI Thesaurus | darbepoetin alfa
A recombinant analog of the endogenous cytokine erythropoietin, an erythropoiesis-stimulating protein. Due to the addition of two carbohydrate chains, darbepoetin alfa exhibits a three-fold greater half-life than does erythropoietin. Similar to erythropoietin, darbopoietin alfa binds to and activates epoetin receptors, thereby inducing the differentiation and maturation of erythrocyte progenitors, stimulating endothelial cell proliferation, and stimulating B-cell proliferation and immunoglobulin production. NCI Thesaurus | darbepoetin alfa
A recombinant analog of the endogenous cytokine erythropoietin, an erythropoiesis-stimulating protein. Due to the addition of two carbohydrate chains, darbepoetin alfa exhibits a three-fold greater half-life than does erythropoietin. Similar to erythropoietin, darbopoietin alfa binds to and activates epoetin receptors, thereby inducing the differentiation and maturation of erythrocyte progenitors, stimulating endothelial cell proliferation, and stimulating B-cell proliferation and immunoglobulin production.
Aranesp
Aranesp is indicated for the treatment of anemia in patients with non- myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.
Amgen, Inc Jul 19 2002
Aranesp
Treatment of anemia associated with chronic renal failure.
Amgen, Inc Sep 17 2001
|
|
|
|
news articles
FDA Approves Extended Dosing of Aranesp (Darbepoetin Alfa) to ... Mar 27, 2006
DG News March 27, 2006 -- Amgen today announced the US Food and Drug Administration (FDA) has approved every-three-week dosing of Aranesp(R) (darbepoetin alfa) for the ...
FDA Approvals: Aranesp, Taxotere, Leukine Mar 28, 2006
Medscape (subscription) March 28, 2006 — The US Food and Drug Administration (FDA) has approved an extended dosing regimen for darbepoetin alfa injection in the treatment of ...
FDA Approves Extended Dosing Of Aranesp Mar 30, 2006
Medical News Today (press release), ...biotechnology company, today announced the US Food and Drug Administration (FDA) has approved every-three-week dosing of Aranesp® (darbepoetin alfa) for the ...
Amgen's Aranesp gets widened dosing schedule Mar 29, 2006
Pharmaceutical Business Review The new approval means Aranesp (darbepoetin alfa) can be used every three weeks for patients with non-myeloid malignancies experiencing anemia (low red blood ...
FDA OKs extended Aranesp dosing Mar 29, 2006
myDNA.com, The US Food and Drug Administration (FDA) has approved every-three-week dosing of Aranesp (darbepoetin alfa) for treatment of chemotherapy-induced anemia in ...
Amgen's Phase 3 RED-HF(TM) Trial Will Evaluate The Clinical Effect ... Mar 19, 2006
Medical News Today (press release), Amgen announced results from a Phase 2 study that showed that treating anemia with Aranesp(R) (darbepoetin alfa) in patients with symptomatic heart failure was ...
Treatment of Anemia in Heart Failure Patients Improves Walking ... Mar 14, 2006
DG News ATLANTA, GA -- March 14, 2006 -- Treatment of anemia with darbepoetin alfa in patients with symptomatic heart failure raises hemoglobin levels and improves ...
New Phase 2 Data Suggest Treatment of Anemia with Aranesp(R) ... Mar 13, 2006
Genetic Engineering News, ...world's largest biotechnology company, announced results from a Phase 2 study that showed that treating anemia with Aranesp(R) (darbepoetin alfa) in patients ...
FDA Approves Extended Dosing Of Amgen's Aranesp To Treat ... Mar 27, 2006
Trading Markets, ...a biotechnology company, revealed that the US Food and Drug Administration has approved every-three-week dosing of Aranesp, or darbepoetin alfa, for the ...
Early Treatment of Chemotherapy-Induced Anemia Linked with Greater ... Mar 17, 2006
Cancer Consultants (press release), ...need for blood transfusions. These medications include Aranesp® (darbepoetin alfa) and Procrit® (epoetin alfa). An issue that ...
Aranesp® Approved for Every Three-Week Dosing Mar 28, 2006
Cancer Consultants (press release), The Food and Drug Administration (FDA) recently approved administration of Aranesp® (darbepoetin alfa) for every three weeks for the treatment of anemia ...
Every-Three-Week Aranesp® Effective Treatment of Chemotherapy ... Mar 1, 2006
Cancer Consultants (press release), Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. ...
Amgen Says Phase 2 Study Shows Treatment Of Anemia With Aranesp ... Mar 13, 2006
Trading Markets, ...of the results of the Phase 2 program and observational studies, Amgen has initiated the Phase 3 RED-HF (Reduction of Events with Darbepoetin alfa in Heart ...
Meta-Analysis Shows Darbepoetin Alfa Treatment Improves Outcomes ... Dec 16, 2005
DG News ALTANTA, GA -- December 16, 2005 -- A meta-analysis of randomized placebo-controlled trials indicates that darbepoetin alfa treatment is associated with ...
Darbepoetin Alfa (Aranesp) Data Suggests Major Response in Anemic ... Dec 16, 2005
DG News ...[Presentation title: A Phase 2, Single-Arm, Open-Label Trial To Evaluate the Effectiveness of Darbepoetin alfa for the Treatment of Anemia in Patients with Low ...
Amgen Updates Product Prescribing Information for Aranesp ... Dec 2, 2005
DG News ...is informing health care professionals that sections of the product prescribing information for Aranesp (darbepoetin alfa) have been updated regarding the fact ...
Coordinated Dosing of Anti-Anemia, Anti-Cancer Therapies Works ... Dec 15, 2005
DG News 15, 2005 -- Patients undergoing treatment for cancer could be prevented from developing anemia and its complications by administering darbepoetin alfa on the ...
New Medicare Claims Monitoring System for Epoetin, Darbepoetin Use Dec 9, 2005
Medscape (subscription) A new Centers for Medicare & Medicaid Services (CMS) policy for monitoring and coverage of erythropoietin (EPO; Epogen) or darbepoetin alfa (Aranesp) for ...
Roche Announces Successful Completion of Four Pivotal Phase III ... Dec 16, 2005
PR Newswire (press release), The third study was designed to evaluate IV CERA in the maintenance of Hb levels in CKD patients on dialysis previously maintained on IV darbepoetin alfa. ...
Investigative Drug Aranesp (Darbepoetin) Effective for ... Dec 14, 2005
DG News ...[Presentation title: Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin alfa Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia. ...
Updated Interim Aranesp(R) Phase 2 Data Suggest Major Response in ... Dec 11, 2005
Business Wire (press release), ...company, today announced updated interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp(R) (darbepoetin alfa) administered every three ...
Benefits Of Aranesp Dosed Every Three Weeks For Chemotherapy ... Dec 12, 2005
Medical News Today (press release), ...interim results from the first multi-center, randomized, double-blind, placebo-controlled, Phase 3 trial of Aranesp® (darbepoetin alfa) administered every ...
Interim aranesp data suggest major response in anemic patients ... Dec 12, 2005
EurekAlert (press release), ...biotechnology company, today announced updated interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp darbepoetin alfa) administered every ...
Drug cuts transfusions in half for chemo patients Dec 15, 2005
Cancerfacts.com, It is the first large, multi-center, comparison trial of Aranesp® (darbepoetin alfa) administered every three weeks in cancer patients with anemia resulting ...
Aranesp® Effective in Low and Intermediate Risk Myelodysplastic ... Dec 7, 2005
Cancer Consultants (press release), Researchers from Italy have demonstrated that long-acting Aranesp (darbepoetin alfa) is as effective as Procrit® (epoetin alfa) for the treatment of patients ...
Drug increases hemoglobin in Myelodysplastic Syndrome Dec 13, 2005
MedIndia, Patients with Bone marrow disorder Myelodysplastic Syndrome (MDS), treated with 500 mcg of Aranesp (Darbepoetin alfa) for every three weeks found to improve ...
Neulasta® and Aranesp® Prevent Adverse Effects of Dose-Dense ... Nov 28, 2005
Cancer Consultants (press release), Treatment with Neulasta® (pegfilgrastim) and Aranesp® (darbepoetin alfa) safely and effectively prevented febrile neutropenia and anemia among women ...
Neulasta® and Aranesp® Provide Effective Hematopoietic Support ... Nov 21, 2005
Cancer Consultants (press release), Researchers from the Dana Farber Cancer Centerhave reported that the prophylactic administration of pegfilgrastim (Neulasta) and darbepoetin alfa (Aranesp) was ...
Anemia in Lung Cancer Patients Often Undertreated Nov 30, 2005
Cancer Consultants (press release), Anemia can be treated by blood transfusions or one of the epoetins such as Procrit® (epoetin alfa) or Aranesp® (darbepoetin alfa). ...
Aranesp: pure red cell aplasia and severe anemia associated with ... Dec 4, 2005
Xagena.it, Amgen has informed Health Care Professionals that sections of the product prescribing information for Aranesp ( Darbepoetin alfa ) have been updated regarding ...
Aranesp® Effective in Myelodysplastic Syndromes Dec 2, 2005
Cancer Consultants (press release), Reference: Stasi R, Abruzzese E, Lanzetta G, Terzoli E, Amadori S. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk ...
FDA Announcement: Aranesp, Epogen, Procrit Associated with Reports ... Dec 2, 2005
PharmaLive.com (press release), ...wishes to inform you that sections of the product prescribing information for Aranesp (darbepoetin alfa) have been updated regarding the fact that, recently ...
|
|
